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F. Dodson, M. Jordan, S. Pham, R. Keenan, B. Griffith, R. Corry, F. Egidi, J.J. Fung, and T.E. Starzl 
THE DISCOVERY of the presence of previously unsus-pected microchimerism in successful long-term liver 
and kidney transplant recipients prompted us to postulate 
that these cells are essential for graft acceptance and the 
induction of donor-specific hyporeactivity.t-3 This observa-
tion provided the basis for the initiation of a new therapeu-
tic strategy which involved infusion of donor bone marrow 
(BM) cells under conventional immunosuppressive treatment 
with tacrolimus and prednisolone:~ The initial outcome of 
sequential in vitro immunologic evaluations performed to 
determine the development of donor-specific hyporeactivity in 
the first 15 BM-augmented and 16 contemporaneous controls 
has been described previously.5.6 We report here the immune 
profile of 102 BM-augmented and 57 control patients who 
were at least 6 months posttransplantation. 
MATERIALS AND METHODS 
Case Material 
Since December 1992. 138 study patients have received simulta-
neous BM + whole organ transplants. Ninety-two recipients of 
whole organs for whom permission could not be obtained for BM 
procurement from cadaveric donors were monitored as controls. 
Sequential immune monitoring was possible in 102 study (liver n = 
31. kidneys n = 27. kidney + pancreas n = 19. kidney + islets n = 
6. heart n = 10. lung n = 8) and 57 control (liver n = 23. kidney n = 
10. kidney + pancreas n = 7. kidney + islets n = 2. heart n = 9. and 
lung n = 6) patients who were at least 180 days posttransplantation 
and for whom donor cells were available. Immunosuppression was 
similar in both groups and consisted of tacrolimus and prednisolone.· 
All patients were analyzed for donor chimerism by FACS andlor 
polymerase chain reaction (PCR) using HlA-specific markers.· 
In Vitro Immune Responsiveness 
Pre- and serially posttransplant (5, 4. and 3 times in 1st. 2nd and 
3rd year respectively) monitoring of recipient's immune status was 
carried out by evaluating the proliferative responses of the periph-
eral blood mononuclear cells (PBMC) to mitogens (conconavalin 
A [ConAl. phytohemagglutinin [PHA)). to recall antigens (tetanus 
toxoid). and to mixed lymphocyte reaction (MLR) with donor and 
third-party cells. The details of the assays were summarized 
elsewhere.h.7 The criteria developed to serially evaluate in vitro 
immune status were also published previously.b.7 Briefly. we have 
classified the transplant recipients based on their in vitro respon-
siveness as either donor-specific hyporeactive. donor-specific inter-
mediate. reactive. or suppressed. 
RESULTS AND DISCUSSION 
In transplant recipients who were augmented with BM, with 
the exception of those receiving hearts, progressive donor-
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Table 1. Results of MLR in 8M-Augmented Organ Transplant Recipients and Its Correlation With Incidence of Chimerism 
DSHI 
No. No. %011 Chimerism 
Type of Transplant Transplants (%) POD:!: SO Steroids (%) 
Uver" 29 15 (48) 872:!: 199 87 86 
Kldneyt 23 10 (43) 605:!:214 50 78 
Kidney + pancreas 19 8 (47) 482 :!: 151 50 86 
Kidney + islet 6 4 (67) 891 :!: 148 75 75 
Heart 10 2 (20) 824:!: 20 NA 50 
Lung 8 5 (62) 587 :!: 190 NA 80 
-Two recIpients were suppressed (nonresponsive to both donor and third-party stimulators). 
TFour organs were lost In pallents who were reactive. 
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No. 
(%) 
14 (45) 
13 (56) 
11 (64) 
2 (38) 
8(80) 
3 (38) 
Reactive 
%011 Chimerism 
POD:!: SO Steroids (%) 
750:!: 157 50 92 
716:!: 207 77 75 
536:!: 179 44 70 
942:!: 236 50 50 
60S:!: 2703 NA 88 
467:!: 164 NA 100 
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Table 2. Results of MLR in Non 8M-Augmented Organ Transplant Recipients and Its Correlation With Incidence of Chimerism 
DSHI 
No. No. % Off 
Type of Transplant Transplant (%) POD::: SO Steroids 
Uver 23 7 (30) 886:t 109 100 
Kidney 10 5 (50) 846:t 75 20 
Kidney + pancreas 7 2 (28) 653 :t 103 50 
Kidney + islet 2 0 0 NA 
Heart 9 2 (22) 752:t 190 NA 
Lung 6 2 (33) 515:t 23 NA 
specific immunomodula.tion was achieved in 50%. On the 
contrary, only 18 of 57 (32%) of the control patients 
exhibited hyporeactivity or intermediate responses to the 
donor (DSHI). It is noteworthy that the temporal relation-
ship of monitoring was comparable in both study and 
control recipients (Tables 1 and 2). 
Liver Transplant Recipients 
BM-augmented liver transplant recipients developed stable 
DSHI within the first year posttransplantation and 13 of 15 
patients retested remained DSHI at the 2-year follow-up 
(range 200 to 600 days). In contrast. in those who received 
only a liver. only three of seven recipients who exhibited 
DSHI previously maintained persistent immunomodulation 
(data not shown). Two of the BM-augmented liver recipi-
ents exhibited low proliferative responses to mitogens. 
donors. and third-party alloantigens and were considered 
suppressed. The majority of study (87%) and control 
(100%) recipients who displayed DSHI were off pred-
nisolone. while weaning from steroids was achieved in only 
50% of those who were reactive in these groups (Tables 1 
and 2). Furthermore. a significant lower incidence of late 
acute cellular rejection was witnessed in BM-augmented 
liver recipients who had previously exhibited DSHI as 
wmpared to those who were MLR reactive. The frequency 
of donor cell chimerism in study recipients displaying DSHI 
was similar to those who were reactive (87'70 and 92%. 
respectively). whereas the frequency of donor cell chimer-
ism detected in the control group was approximately 601"0. 
Kidney Transplant Recipients 
The outcome in the BM-augmented and control kidney 
transplant recipients was comparahle for all the parameters 
tested including immune status. percent off steroids. and 
incidence of donor-specific chimerism (Tahles I and 2).7 
Four BM-augmented kidney transplant recipients who ex-
perienced late rejection episodes lost their grafts. Two of 
these recipients developed DSHI during the first year post-
transplant hut re\,erted tn l\ILR rcactive status prior to 
evolvement nf the late rejection episode. ultimatelv leading to 
graft loss. It is noteworthy that a higher percent of BM-
augmented kidney + rancreas and kidney -'- Islet recipients 
exhihited DSHI in comparisnn to that of control patiellls. 
Reactive 
Chimerism No. %01 Chimerism 
(%) (%) POD::: SO Steroids (%) 
67 16 (70) 871 :t 87 56 50 
60 5 (50) 674:t 346 60 75 
50 5 (72) 453 :t 128 20 40 
NA 2 (100) 334 :t 68 50 100 
100 7 (78) 536:t 263 NA :"0(43 
100 4 (67) 495 :t 16 NA 50 
Thoracic Organs 
Most of the heart transplant recipients in the study and 
control group retained donor-specific responsiveness (Ta-
bles 1 and 2). On the contrary, in lung allograft recipients a 
twofold higher incidence of induction of DSHI (62%) was 
observed in BM-augmented patients as compared to that of 
controls (33%). The frequency of donor cell chimerism was 
80% in BM-augmented and nonaugmented heart and lung 
transplant recipients who exhibited DSHI. whereas it was 
only 50% in controls who were MLR reactive. Although not 
statistically significant. there was a trend toward a lower 
incidence of rejection within the first 100 days after trans-
plantation in the study heart recipients as compared to 
similarly treated historical controls. H Bronchiolitis obliter-
ans (OB). a form of chronic rejection in lung recipients. was 
witnessed in two of six controls and in none of the eight 
study patients with a follow-up of 18 months posttransplan-
tation. 
In summary. the simultaneous infusion of donor BM cells 
in allograft recipients was associated with an increase in the 
incidence of donor cell chimerism in all organ allografts. 
and with a twofold increase of DSHI in liver and lung 
recipients. Furthermore. BM-augmented transplant recipi-
ents who developed stable donor-specific hyporeactivity 
experienced less late allograft rejection and improved long-
term outcome. 
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